• Veeva Systems (NYSE:VEEV) said Regeneron Pharmaceuticals and Biogen have selected Veeva Vault CRM for their global operations in new partnerships.
• The agreements expand adoption of Veeva's AI powered commercial platform among large pharmaceutical companies.
• The new deals follow earlier news on Eli Lilly's commitment to Vault CRM and changes in Veeva's sales leadership.

Readers watching Veeva's AI driven software footprint in life sciences may also want to review other stocks tied to the build out of AI infrastructure through 55 AI infrastructure stocks.

Veeva Systems, a US based healthcare software company with a market cap of about $40.4b, provides cloud tools that help life sciences companies manage customer relationships and regulated content across global markets including North America, Europe and the Asia Pacific.

How do the Regeneron and Biogen wins fit into Veeva Systems’ strategy?

Regeneron and Biogen committing to Veeva Vault CRM globally helps Veeva Systems deepen its role as a commercial system of record for large pharma. Both are using AI powered field engagement and the Agentic Call Report, which aligns with Veeva’s push toward an agentic commercial model built on its Vault CRM Suite.

Does this news change the current Veeva Systems Narrative?

This news lines up closely with the Narrative’s catalyst that large pharma customers are consolidating more spend on Veeva’s Commercial Cloud as AI agents are embedded into Vault. It supports the idea that interoperability progress and AI integration can drive broader suite adoption, while customer concentration risk remains an important counterpoint to track.

If we take a look at the community Narrative for Veeva Systems, we can see how this news fits into the bigger investment story.

What should investors watch next to see if these CRM deals really matter for Veeva Systems?

The key test is whether these contracts translate into broader Vault CRM Suite rollouts and AI agent usage over the next few quarters, rather than just initial deployments. Investors can watch for evidence of multi product expansions, references to Commercial Evidence usage, and updates on top 20 pharma adoption in upcoming earnings calls.

For the full picture including more risks and rewards, check out the complete Veeva Systems analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.